A randomised controlled trial of an intervention to promote the effects of Health Enhancing Physical Activity (HEPA) on physical and psychosocial outcomes in patients with mild Chronic Obstructive Pulmonary Disease (COPD) who are being treated with tiotropium

ISRCTN ISRCTN99038914
DOI https://doi.org/10.1186/ISRCTN99038914
Secondary identifying numbers 200601
Submission date
24/09/2007
Registration date
13/02/2008
Last edited
13/05/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims?
Chronic obstructive pulmonary disease (COPD) is the name for a collection of lung diseases. People with COPD have difficulties breathing due to the narrowing of their airways. Pulmonary rehabilitation (PR) is a programme of exercise and education that is recommended to help patients with COPD. The aim of this study was to determine the additional effect of a PR programme on patients with mild COPD who are taking tiotropium (a drug that widens the airways in the lungs).

Who can participate?
Adult patients with mild COPD.

What does the study involve?
Patient records from local GP practices were searched to identify early-stage COPD patients. All patients were prescribed tiotropium for a minimum of 4 weeks before attending an assessment where their height and weight were measured and they underwent a lung function test and a walking test. Study questionnaires were also completed. Participants were then randomly allocated to one of two groups. One group took part in 8 weeks of once weekly, 90-minute supervised exercise and education sessions and were also encouraged to take part in a home-based exercise program. An exercise diary and pedometer was used to record home-based exercise participation. The other group were requested to continue normal care as instructed by their GP. All participants then took part in a follow-up assessment.

What are the possible benefits and risks of participating?
The benefits of taking part included regular physical activity under the guidance of a trained exercise practitioner. The education sessions were also deemed valuable as they were used to increase participants’ awareness of how to manage the symptoms of COPD. There are no known risks associated with participating in this study.

Where was the study run from?
University of Exeter (UK).

When is the study starting and how long is it expected to run for?
The study started in 2007. GP practice and participant recruitment was completed in 2009, with study findings published in 2010.

Who is funding the study?
The International Primary Care Respiratory Group (UK).

Who is the main contact?
Professor Adrian Taylor
A.H.Taylor@ex.ac.uk

Contact information

Prof Adrian Taylor
Scientific

School of Sport and Health Sciences
St. Luke's Campus
University of Exeter
Magdalen Road
Exeter
EX1 2LU
United Kingdom

Phone +44 (0)1392 264747
Email a.h.taylor@ex.ac.uk

Study information

Study designSingle-centre single-blind randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeTreatment
Scientific titleA randomised controlled trial of an intervention to promote the effects of Health Enhancing Physical Activity (HEPA) on physical and psychosocial outcomes in patients with mild Chronic Obstructive Pulmonary Disease (COPD) who are being treated with tiotropium
Study acronymHEALTH
Study objectivesChronic Obstructive Pulmonary Disease encompasses chronic bronchitis, emphysema, chronic obstructive airways disease, chronic airflow limitation, and some cases of chronic asthma. The disease is chronic, slowly progressive, irreversible and debilitating, and has a devastating effect on individuals, causing significant mortality and morbidity and carrying a huge cost to both the health service and society. The symptoms of Chronic Obstructive Pulmonary Disease include increasing breathlessness and fatigue which gradually removes the individual's ability to partake in everyday activities such as walking, shopping and even minor physical exertion. As patients tire quickly, progression of the disease requires significant modification to lifestyle and activity and has consequences on psychological well being, employment and finances with impacts on social functioning, family and mood.

Hypothesis:
What is the additional effect of a Health Enhancing Physical Activity programme (HEPA) on physiological and psychosocial outcomes in participants with mild Chronic Obstructive Pulmonary Disease (COPD) who are receiving tiotropium in accordance with National Institute for Clinical Excellence (NICE) guidelines?
Ethics approval(s)Devon and Torbay Research Ethics Committee, 05/06/2007, ref: 07/Q2102/42
Health condition(s) or problem(s) studiedChronic Obstructive Pulmonary Disease
InterventionA single-centre, single-blind randomised controlled trial of participants with mild COPD randomised equally to health enhancing physical activity intervention or normal care.

Health Enhancing Physical Activity Programme (HEPA):
Once weekly exercise and education session for 8 weeks, delivered by a qualified Exercise Practitioner, with instruction on exercising at home, exercise diaries and pedometer.

Control:
Continuation of normal care from General Practitioner (GP).

All participants will be followed up for a period of one year.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Tiotropium
Primary outcome measure1. Maximal exercise capacity measured using an Incremental Shuttle Walking Test (ISWT), measured at screening assessment (baseline - 5 weeks), baseline, weeks 9, 25 and 52
2. Total score on Chronic Respiratory Disease Questionnaire, measured at baseline, weeks 9, 13, 25, 52

Timepoints:
Visit 1: Study Week (-5): Screening assessment
Visit 2: Study Week 0: Baseline/randomisation
Visit 3: Study Week 9: End of 8 week intervention period
Study Week 13: 3 months post-baseline questionnaire survey
Visit 4: Study Week 25: 6 month post-baseline follow-up assessment
Visit 5: Study Week 52: 12 months post-baseline follow-up assessment
Secondary outcome measures1. Spirometry including inspiratory capacity, measured at screening assessment (baseline - 5 weeks), baseline, weeks 9, 25, 52
2. MRC dyspnoea score, measured at screening assessment (baseline - 5 weeks), baseline, weeks 9, 25, 52
3. Questionnaires:
3.1. Lung Information Needs Questionnaire, measured at baseline, weeks 9, 25, 52
3.2. Chronic Respiratory Disease Questionnaire: domain scores, measured at baseline, weeks 9, 13, 25, 52
3.3. Hospital Anxiety and Depression Scale scores, measured at baseline, weeks 9, 13, 25, 52

Exploratory:
1. Self-efficacy to regulate exercise questionnaire, measured at baseline, weeks 9, 13, 25, 52
2. Seven Day Physical Activity Recall Questionnaire, measured at baseline, weeks 9, 13 , 25, 52
3. Physical Self Perception Questionnaire, measured at baseline, weeks 9, 13, 25, 52
4. Smoking Status Questionnaire, measured at baseline, weeks 9, 13, 25, 52
5. Perceived Autonomy Support measure (Health Care Climate Questionnaire), measured at week 9

Timepoints:
Visit 1: Study Week (-5): Screening assessment
Visit 2: Study Week 0: Baseline/randomisation
Visit 3: Study Week 9: End of 8 week intervention period
Study Week 13: 3 months post-baseline questionnaire survey
Visit 4: Study Week 25: 6 month post-baseline follow-up assessment
Visit 5: Study Week 52: 12 months post-baseline follow-up assessment
Overall study start date01/11/2007
Completion date30/04/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants100
Key inclusion criteria1. Adult patients (male and female) with clinical diagnosis of mild COPD
2. Smoking history greater than 10 pack years
3. Suitable for treatment with tiotropium according to NICE guidelines
4. Willing and able to undertake a health enhancing physical activity programme
Key exclusion criteria1. Body Mass Index (BMI) greater than 30 or less than 18 kg/m^2
2. History of asthma
3. Recent respiratory tract infection
4. Oxygen desaturation at rest less than 90%
5. Presence of serious co-morbid condition (orthopaedic, cardiovascular, muscular or neurological condition) that would interfere with regular exercise training
6. Prior participation in a pulmonary rehabilitation programme
Date of first enrolment01/11/2007
Date of final enrolment30/04/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Exeter
Exeter
EX1 2LU
United Kingdom

Sponsor information

University of Exeter (UK)
University/education

Northcote House
The Queen's Drive
Exeter
EX4 4QJ
England
United Kingdom

Phone +44 (0)1392 661000
Email a.c.richards@exeter.ac.uk
Website http://www.exeter.ac.uk/
ROR logo "ROR" https://ror.org/03yghzc09

Funders

Funder type

Charity

International Primary Care Respiratory Group (UK) (ref: 200601)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article feasibility results 01/06/2010 Yes No